BCL2 and Miyoshi myopathy: As the mechanism of caspases activation by marizomib is different than in bortezomib-mediated activation and relies primarily on caspase-8 activation, it allows to overcome the resistance of MM cells to apoptosis also with Bcl-2 mutations, leading to overexpression of Bcl-2.